The Weekly Roundup: January 19-23

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

The “6-7” Advances for Dermatologists to Look Forward to in 2026

Explore the latest dermatology trends for 2026, including innovative therapies for psoriasis, atopic dermatitis, and hair loss advancements.

Q&A: Saami Khalifian, MD, FAAD, on Integrating BOTOX Cosmetic into Lower Face and Neck Rejuvenation

BOTOX Cosmetic's FDA approval for platysma bands revolutionizes non-surgical neck rejuvenation, offering dermatologists a new tool for effective patient care.

Clinicians See Intersection of Weight Loss and Facial Aging

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

BioMendics CEO Karen McGuire, PhD, on Disease-Modifying Strategies for EB Simplex

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

WhatsApp Pilot Highlights Persistent Care Gaps in CSU

A WhatsApp-based pilot study revealed high patient knowledge and significant challenges in managing CSU among Spanish speakers.

Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

The Burden of the Atopic March: Real-World Data on Pediatric AD and Allergic Comorbidities in Japan

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

Practical Decisions Behind PDT for Actinic Keratosis

Michael O'Donoghue, MD, discusses tailoring PDT for AK, emphasizing patient preferences and flexible treatment strategies.

Outlining the Clinical Development Strategy of TolaSure for EB Simplex

BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.

Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

Journal Digest: January 21, 2026

This review of the latest dermatologic studies includes insights on a novel ultrasound technique for midface rejuvenation, sirolimus for reducing cSCC risk, dermatologists' role in social media, and more.

Twelve Months of LLLT Show Sustained Benefit in Alopecia

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.

Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables

Obagi Medical's ALOHA Program launches Obagi saypha MagIQ, pioneering real-world evaluation of a new HA filler.

Smartphone-Based Education Reduces Short-Term Relapse in Pediatric Atopic Dermatitis

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.

Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus

DELTA CARE 1 is the first phase 3 investigation of a pan-JAK inhibitor specifically for lichen sclerosus.

New Research Highlights Significant Knowledge Gaps in Patients Using Oral Acne Medication

New research uncovers significant knowledge gaps among Chinese acne patients regarding oral medications, highlighting the need for improved education strategies.

Del Rosso's What's New in the Medicine Chest 2026: Topicals

James Del Rosso, DO, discusses innovative topical therapies for dermatologic conditions.

Precision Dermatology Takes Center Stage at ISDS 2025

The 2025 Inflammatory Skin Disease Summit unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.

Atopia Therapeutics Reports Positive Preclinical Data for ATP-R13 as Disease-Modifying Oral AD Therapy

Atopia Therapeutics advances ATP-R13 as a promising oral therapy for atopic dermatitis, showing significant efficacy and enhanced patent protection.

LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe AD.

Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

The Aesthetic Edge: January 2026

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of January.

Welcoming a New Year of Progress and Clinical Innovation

Explore the latest advancements in dermatology for 2026, focusing on clinical innovation, emerging research, and practical insights for improved patient care.

Highlighting Upcoming Aesthetic Innovations in 2026

Tina Alster, MD; Daniel Schlessinger, MD; and Mary Lupo, MD, shared their insights on upcoming aesthetic innovations at ASDS in Chicago.

National Survey Highlights Unmet Needs and TCS Concerns in Chronic Inflammatory Skin Diseases

A nationwide survey reveals significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

Long-Term Real-World Data Show Cutaneous Benefits of Belimumab

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

Galderma Presents Phase 3 Relfydess Data and Dysport Innovations at TOXINS 2026

Galderma showcased relabotulinumtoxinA and abobotulinumtoxinA at TOXINS 2026, highlighting innovative injectables with sustained results and high patient satisfaction.

Derm Dispatch: The Growing Role of AI in Customized Dermatologic Care

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.